| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.03 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.03 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |